Accord Farma S.a. DE C.v. Pharmaceutical Import Profile — Mexico (DGFT 2022–2026)

Name: Accord Farma S.a. DE C.v. Pharmaceutical Import Records from India — 5 Products, $6.5M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Accord Farma S.a. DE C.v. — Pharmaceutical Importer Profile (2026) | 5 Products, $6.5M Trade | TransData Nexus

Accord Farma S.a. DE C.v.

Pharmaceutical Importer · Mexico · Cardiovascular Focus · $6.5M Total Trade · DGFT Verified

Accord Farma S.a. DE C.v. is a pharmaceutical importer based in Mexico with a total trade value of $6.5M across 5 products in 3 therapeutic categories. Based on 307 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Accord Farma S.a. DE C.v. sources from 2 verified Indian suppliers, with Intas Pharmaceuticals Limited accounting for 99.5% of imports.

Accord Farma S.a. DE C.v. — Import Portfolio & Supplier Network

Accord Farma S.a. DE C.v. import network — 5 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Accord Farma S.a. DE C.v.?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Intas Pharmaceuticals Limited	$5.6M	171	99.5%
Rpg Life Sciences Limited	$26.6K	2	0.5%

Accord Farma S.a. DE C.v. sources from 2 verified Indian suppliers across .

What Formulations Does Accord Farma S.a. DE C.v. Import?

Formulation	Value	Ships
Pharma drugs and medi lesprek 40MG telmisartan 3x10tacc-mxe2 as per	$1.2M	37
Pharma drugs and medi lesprek 40MG telmisartan 3x10t acc mx e2 as per	$602.5K	17
Pharma drugs and medi lesprek 40MG	$310.6K	11
Pharmaceutical drugs and medicine	$250.0K	5
Pharmaceutical drugs and medicine :acoexcel 300MG/50ML INJ. 1x1 vial e1 Each ML contains paclitaxel USP...6.00MG	$221.2K	6
Pharma drugs and medi acortral-50MG 14	$193.9K	10
Pharmaceutical drugs and medicine	$153.1K	5
Pharma drugs and medi lesprek 40MG telmisartan 3x10t as per	$131.3K	3
Pharmaceutical drugs and medicine	$107.0K	3
Pharmaceutical drugs and medicine :cavepetoposide 100MG/5ML 1x1vacc mexico eachfilm coated tablet contains	$103.7K	3
Pharma drugs and medi nuvaplast	$100.0K	2
Ph.dru.& med.: pelgraz injection	$100.0K	2
Pharmaceutical drugs and medicine : nuvaplast 450MG/45ml1x1v e1 Each ML contains: carboplatin ph. eur.. ##### 10 MG	$100.0K	2
Pharmaceutical drugs and medicine : nuvaplast 450MG/45ml1x1v e1 Each ML contains: carboplatin ph. eur.. ##### 10	$100.0K	2
Pharma drugs and medi nuvaplast 450MG/45ml1x1v e1 Each ML contains:carboplatin ph. eur.10 MG water for injections	$100.0K	2

Accord Farma S.a. DE C.v. imports 57 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 5 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Telmisartan	Cardiovascular	$5.2M	279	0.0%	14
2	Carboplatin	Oncology	$700.0K	14	1.0%	10
3	Etoposide	Oncology	$336.4K	10	3.1%	5
4	Docetaxel	Oncology	$100.0K	2	0.3%	9
5	Mitoxantrone	Advanced Oncology	$100.0K	2	5.3%	2

Accord Farma S.a. DE C.v. imports 5 pharmaceutical products across 3 categories into Mexico totaling $6.5M.

Accord Farma S.a. DE C.v. — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Accord Farma S.A. de C.V. is a Mexican pharmaceutical company specializing in the importation and distribution of generic pharmaceutical products. Established in 2006, the company is headquartered in Mexico City, with its office located at Jaime Balmes #11, Torre D, Piso 3, Col. Los Morales Polanco, C.P. 11510, Miguel Hidalgo. (accordfarma.com.mx) Accord Farma operates as the Mexican representative of Intas Pharmaceuticals Ltd., a prominent Indian pharmaceutical manufacturer. (accordfarma.com.mx) The company plays a significant role in Mexico's pharmaceutical distribution network, focusing on the importation of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections.

2Distribution Network

Accord Farma's distribution network is centered in Mexico City, where it manages its operations and logistics. While specific details about warehouse locations and logistics capabilities are not publicly disclosed, the company's strategic partnership with Intas Pharmaceuticals Ltd. suggests a robust supply chain infrastructure. This partnership likely facilitates efficient distribution within Mexico and potentially to other regions, leveraging Intas's global manufacturing and distribution capabilities.

3Industry Role

In Mexico's pharmaceutical supply chain, Accord Farma S.A. de C.V. functions primarily as a pharmaceutical importer and distributor. By sourcing finished pharmaceutical formulations from Intas Pharmaceuticals Ltd., the company ensures a steady supply of generic medications to the Mexican market. This role is crucial in providing affordable healthcare options to the population, especially in the generic drug segment.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Accord Farma S.a. DE C.v.

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Accord Farma's sourcing strategy exhibits a high degree of concentration, with 99.5% of its imports from India supplied by Intas Pharmaceuticals Ltd. This single-source dependency could pose risks related to supply chain disruptions, such as production delays or regulatory changes affecting the supplier. However, the consistent volume of shipments—171 out of 173 total shipments from India—indicates a stable and reliable relationship between Accord Farma and Intas Pharmaceuticals Ltd. The remaining 0.5% of imports from RPG Life Sciences Limited suggests minimal diversification in sourcing.

2Supply Chain Resilience

Accord Farma's supply chain resilience is closely tied to its exclusive partnership with Intas Pharmaceuticals Ltd. The lack of backup suppliers for the majority of its imports indicates a potential vulnerability to supply chain disruptions. Additionally, the limited diversity in imported formulations, with only five products across three therapeutic categories, suggests a narrow product range. This concentration may impact the company's ability to adapt to market changes or shifts in demand. Furthermore, the reliance on a single supplier raises concerns about exposure to shipping route disruptions and the need for stringent regulatory compliance from Intas Pharmaceuticals Ltd.

Strategic Implications

Importing Pharmaceuticals into Mexico — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Mexico

1Regulatory Authority & Framework

In Mexico, the Federal Commission for the Protection against Sanitary Risk (COFEPRIS) is the primary regulatory authority overseeing pharmaceutical imports. Key legislation governing pharmaceutical imports includes the General Health Law and the Health Supplies Regulation. These regulations establish the framework for the importation, registration, and marketing of pharmaceutical products in Mexico. The marketing authorization pathway for Indian generics involves obtaining COFEPRIS approval, which requires compliance with specific documentation, quality standards, and clinical data to ensure the safety and efficacy of the imported products.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in Mexico mandate that importers obtain a sanitary license from COFEPRIS. This license ensures that imported products meet the necessary health and safety standards. Good Manufacturing Practice (GMP) certificates recognized by COFEPRIS, such as those from the European Union (EU GMP), World Health Organization (WHO GMP), and Pharmaceutical Inspection Co-operation Scheme (PIC/S), are essential for the importation of pharmaceutical products. Accord Farma, as a distributor, must ensure that its suppliers hold valid GMP certifications to comply with Mexican regulations. Additionally, Accord Farma must possess wholesale distribution authorization from COFEPRIS to legally distribute pharmaceutical products within Mexico.

Accord Farma S.a. DE C.v. — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Accord Farma's product strategy focuses on importing generic medications in the cardiovascular and oncology therapeutic areas. The significant import value of Telmisartan, a cardiovascular drug, indicates a strong market demand for affordable hypertension treatments. The inclusion of oncology drugs like Carboplatin, Etoposide, Docetaxel, and Mitoxantrone reflects the company's commitment to providing essential cancer therapies. This strategic focus aligns with the growing healthcare needs in Mexico, where chronic diseases and cancer are prevalent.

2Sourcing Profile

Accord Farma's sourcing strategy is centered on importing generic drugs from India, particularly from Intas Pharmaceuticals Ltd. The company's preference for finished pharmaceutical formulations, such as tablets, capsules, syrups, and injections, indicates a focus on ready-to-market products. India's established pharmaceutical manufacturing capabilities and cost-effectiveness make it a suitable source for Accord Farma's procurement needs. This sourcing approach allows Accord Farma to offer a range of generic medications to the Mexican market efficiently.

3Market Positioning

Seller's Guide — How to Become a Supplier to Accord Farma S.a. DE C.v.

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter Accord Farma's supply chain. The company's limited diversification in sourcing and its reliance on a single supplier for the majority of its imports suggest potential gaps that new suppliers could fill. Introducing additional products or alternative sources for existing products could help mitigate supply chain risks and enhance Accord Farma's product offerings. For Indian exporters, this presents an opportunity to establish partnerships and expand their market presence in Mexico.

2Requirements & Qualifications

Indian exporters seeking to supply Accord Farma S.A. de C.V. must ensure that their products comply with Mexican regulatory standards. This includes obtaining GMP certifications recognized by COFEPRIS, such as EU GMP, WHO GMP, or PIC/S. Products must also meet labeling requirements, including Spanish language labeling and serialization mandates. Additionally, exporters should be prepared to provide necessary documentation for import licensing and quality assurance to facilitate the approval process with Accord Farma and Mexican authorities.

3How to Approach

Frequently Asked Questions — Accord Farma S.a. DE C.v.

What products does Accord Farma S.a. DE C.v. import from India?

Accord Farma S.a. DE C.v. imports 5 pharmaceutical products across 3 categories. Top imports: Telmisartan ($5.2M), Carboplatin ($700.0K), Etoposide ($336.4K), Docetaxel ($100.0K), Mitoxantrone ($100.0K).

Who supplies pharmaceuticals to Accord Farma S.a. DE C.v. from India?

Accord Farma S.a. DE C.v. sources from 2 verified Indian suppliers. The primary supplier is Intas Pharmaceuticals Limited (99.5% of imports, $5.6M).

What is Accord Farma S.a. DE C.v.'s total pharmaceutical import value?

Accord Farma S.a. DE C.v.'s total pharmaceutical import value from India is $6.5M, based on 307 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Accord Farma S.a. DE C.v. focus on?

Accord Farma S.a. DE C.v. imports across 3 categories. The largest: Cardiovascular (80.8%), Oncology (17.6%), Advanced Oncology (1.5%).

Get Full Accord Farma S.a. DE C.v. Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 3 company name variants from customs records. For current shipment-level data, contact TransData Nexus.